Company intelligence / Profile preview

Prextor

Geneva, Switzerland

Ownership: Private
Employees: ~10
Development stage: Other

Overview

In May 2020, Lundbeck announced that the Phase II AMBITION trial of the lead candidate foliglurax failed to meet its primary endpoint, showing no statistically significant difference from placebo in reducing daily awake 'OFF' time in patients with Parkinson's disease. Clinical development was subsequently discontinued.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Domain TherapeuticsMerck KGaA

Beyond the preview

Go deeper on Prextor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prextor.

Explore the full profile